about us
capabilities
publications

space

NEWS:

November 2013
In Vivo, "Surpassing Expectations: Increasing Deal Value Through Better Drug Value Propositions"

This article, by Bruckner Group partners Michael Russo and David Balekdjian, explains how biotech and pharma companies developing promising new therapies can greatly increase the value of their drug assets and the value of future partnering deals, by building comprehensive payer strategies. This especially requires initiating the value proposition development process early in clinical development, and proactively building a multi-faceted payer strategy containing four other key components. Industry executives quoted in the article indicate that with these in hand, small companies can position themselves to create greater interest in their assets from prospective partners, and to increase the value of partnering deals. However, these executives indicate that few if any companies are doing this properly, if even at all. As a result, small companies are falling far short of partnering deals that would otherwise be achievable, and are unintentionally diminishing the value of their assets. The article presents an effective roadmap for overcoming these issues. Here is the link:

http://www.elsevierbi.com/publications/in-vivo/31/10/surpassing-expectations-increasing-deal-value-through-better-drug-value-propositions

June 2013
Op-Ed in The National (UAE), "The UAE's Biotechnology Sector Needs An Injection of Boldness"

This Op-Ed, written by Cyrus Hodes and The Bruckner Group's David Balekdjian, explains that the UAE is well-positioned to develop a world-class biotechnology sector, except for one key missing ingredient. Here is the link:

http://www.thenational.ae/business/industry-insights/economics/the-uaes-biotechnology-sector-needs-injection-of-boldness

Legacy Publications:
Here, we are going to highlight some of the most impactful papers and articles we have authored. What we are most proud of, reviewing our publication legacy, is how on-target Bruckner has consistently been with our analysis and predictions over the last 12 years. It's a track record we know our clients have greatly benefitted from:

February 2008: Nature Biotechnology, "Weighing The Outcomes": This expansive paper, which was elevated to become the Feature in this issue, explores the impact of U.S. payer policies on the development of new biological and specialty therapies. Quickly becoming a highly-impactful reference paper, "Weighing The Outcomes" puts forward a framework, still fully valid (if not even more so), for the pathway to developing new therapeutics that align with payers needs and thus avoid restrictive payer access programming, alongside the needs of patients and physicians. Interestingly, the predictions made in the paper have all subsequently come true. This article also warned against a barnstorming industry rush to a few target areas such as cancer, a move directly in conflict with the future of access and coverage.

February 2006: Business Week, "Irrational Exubera-nce for Pfizer": This article, published at the time that Pfizer's Exubera received its FDA approval, made the then-highly contrarian prediction that Pfizer's Exubera was not only going to not become the blockbuster that every industry analyst predicted, but rather, would likely fail commercially. We were the only ones who made this prediction, and we received tremendous criticism for it. 18 months later, Pfizer withdrew the drug from the market and took a $3 billion charge against earnings—one of the most costly drug failures in industry history. Exubera failed for the very reasons indicated in this article.

April 2005: Pharmaceutical Executive, "The Year Payers Stopped Threatening": This article, building upon a series of previous articles published in Pharmaceutical Executive, provides a framework for how and why payers have adopted aggressive tactics to reduce access to new small molecule and biological therapeutics that do not offer healthcare value at a level that address payer needs. The paper also presents ideas for how new drugs need to be developed in order to be commercially successfully in a new era where success is being dominated by payers, not only physicians and patients.